Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine
- PMID: 19616498
- PMCID: PMC2734870
- DOI: 10.1016/j.vaccine.2009.06.098
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine
Abstract
The aim was to identify an appropriate infant pneumococcal vaccination strategy for resource poor countries. Fijian infants received zero, one, two, or three doses of 7-valent pneumococcal conjugate vaccine (PCV) in early infancy. Following three PCV doses, geometric mean concentration (GMC) to all seven serotypes were > or = 1.0 microg/mL, and >85% of children achieved antibody levels > or = 0.35 microg/mL at 18 weeks. Following two doses, GMC were lower for 6B, 14, and 23F, but higher for 19F compared with three doses. Following a single dose, significant responses were seen for all serotypes post-primary series compared with the unvaccinated. By 12 months, differences between two and three doses persisted for serotype 14 only. Although GMC following three doses are higher than after two doses, the differences were small. A single dose may offer some protection for most serotypes.
Figures
Similar articles
-
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.Lancet Infect Dis. 2021 Jun;21(6):834-846. doi: 10.1016/S1473-3099(20)30735-0. Epub 2021 Jan 28. Lancet Infect Dis. 2021. PMID: 33516293 Clinical Trial.
-
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.Vaccine. 2013 Jan 21;31(5):777-83. doi: 10.1016/j.vaccine.2012.11.076. Epub 2012 Dec 8. Vaccine. 2013. PMID: 23228814 Free PMC article. Clinical Trial.
-
Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa.Pediatr Infect Dis J. 2002 Nov;21(11):1004-7. doi: 10.1097/00006454-200211000-00006. Pediatr Infect Dis J. 2002. PMID: 12442020 Clinical Trial.
-
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.Lancet Infect Dis. 2020 Dec;20(12):1426-1436. doi: 10.1016/S1473-3099(20)30289-9. Epub 2020 Aug 25. Lancet Infect Dis. 2020. PMID: 32857992 Free PMC article. Clinical Trial.
-
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.Vaccine. 2011 Jun 15;29(27):4499-506. doi: 10.1016/j.vaccine.2011.04.038. Epub 2011 May 1. Vaccine. 2011. PMID: 21539882 Free PMC article. Clinical Trial.
Cited by
-
Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial.BMJ Open. 2018 Jun 8;8(6):e019795. doi: 10.1136/bmjopen-2017-019795. BMJ Open. 2018. PMID: 29884695 Free PMC article.
-
Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial.BMJ Open. 2021 Nov 29;11(11):e056505. doi: 10.1136/bmjopen-2021-056505. BMJ Open. 2021. PMID: 34845082 Free PMC article.
-
Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.J Allergy Clin Immunol. 2012 Mar;129(3):794-800.e2. doi: 10.1016/j.jaci.2011.11.043. Epub 2012 Feb 2. J Allergy Clin Immunol. 2012. PMID: 22305678 Free PMC article. Clinical Trial.
-
Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.Vaccine. 2015 Oct 13;33(42):5708-5714. doi: 10.1016/j.vaccine.2015.07.059. Epub 2015 Jul 29. Vaccine. 2015. PMID: 26232540 Free PMC article. Clinical Trial.
-
Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study.Trials. 2022 Jan 15;23(1):39. doi: 10.1186/s13063-021-05949-4. Trials. 2022. PMID: 35033180 Free PMC article. Clinical Trial.
References
-
- The WHO Young Infants Study Group. Conclusions from the WHO multicenter study of serious infections in young infants. Pediatric Infect Dis J. 1999;18:S32–4. - PubMed
-
- Pneumococcal Conjugate Vaccine for childhood immunization-WHO position paper. World Health Organization Weekly Epidemiological Record No. 12. 2007;82:93–104. - PubMed
-
- Denny FW, Loda FA. Acute respiratory infections are the leading cause of death in children in developing countries. American Journal of Tropical Medicine & Hygiene. 1986;35(1):1–2. - PubMed
-
- Hausdorrf WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. CID. 2000;30(1):122–40. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical